Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

NCT05245071 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05245071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2022
Completion date
November 20, 2024
Enrollment
22 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer